HELX vs IBBQ

HELXCFranklin Genomic Advancements ETF

IBBQAInvesco Nasdaq Biotechnology ETF

In short

HELX Most genomics funds hand you an index. Franklin's take is a stock-picker's portfolio of roughly 60 global names tied to gene sequencing, gene therapy and precision medicine, launched in 2020 with a plain mandate: capital appreciation.

IBBQ The broad Nasdaq biotech benchmark, bought cheap. IBBQ tracks the whole listed biotech and pharma field, roughly 300 names, for 0.19% a year, well under half the typical fee in its category.

Stated mandate

HELX The Fund seeks capital appreciation.

IBBQ The Fund tracks the Nasdaq Biotechnology Index and normally invests at least 90% of its assets in index constituents. The index covers Nasdaq-listed companies classified as biotechnology or pharmaceutical companies.

Why people hold it

• HELX A concentrated bet, not a basket: about 60 global holdings across the genomics chain, so individual breakthroughs actually move the fund instead of being diluted by hundreds of names.
• Global by design. The mandate is not fenced to US listings, which matters in a field where sequencing and gene-therapy leaders sit in Europe and Asia too.
• Fee sits right at the middle of the genomics and biotech peer group at 0.50%, so you are not paying a premium over the typical thematic competitor for a discretionary approach.
• Live since 2020, giving it a multi-year record through a brutal stretch for biotech, rather than a launch-window track record.

• IBBQ At 0.19% a year, the lowest fee among its closest biotech rivals and less than half the category median.
• Holds roughly 300 Nasdaq-listed biotech and pharma companies, so one failed trial or one blockbuster is a slice of the fund, not the whole story.invesco.com
• Rules first: normally at least 90% of assets sit in Nasdaq Biotechnology Index constituents. No manager guessing which pipeline pays off.invesco.com
• Stands in the top quartile of the biotech and genomics funds we grade, keeping company with far larger rivals like XBI and IBB.

Worth knowing

• HELX It is a small, thinly traded fund. Use limit orders, expect wider spreads than the big index names, and know that small ETFs carry more closure risk than entrenched ones.
• The low-cost, high-liquidity lane in this category belongs to index products like IBBQ (0.19%) and IBB (0.44%). HELX's case rests on the manager's picks, not on price or trading ease.
• Genomics is a growth-style, high-volatility corner of health care. Clinical trial results and rate moves can swing a 60-stock portfolio hard in both directions.

• IBBQ Thinly traded next to the category's giants, so bid-ask spreads can widen. Limit orders matter more here than in a heavily traded fund.
• One sector, and a jumpy one: biotech and pharma prices move on trial data and regulatory decisions, a rougher ride than a broad-market fund.invesco.com
• Launched in 2021, so a shorter live record and a smaller asset base than the category's long-standing funds.

Full HELX profile⁠

Full IBBQ profile⁠